Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study

NCT01320202 is registered in ClinicalTrials.gov with Rockwell Medical Technologies, Inc. as lead sponsor.

NCT NCT01320202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01320202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Phase III Study of Dialysate Containing Soluble Ferric Pyrophosphate (SFP) in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents (CRUISE 1) Study
Lead sponsor
Rockwell Medical Technologies, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
November 30, 2013
Enrollment
305 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure chronic requiring hemodialysis